

AMENDMENTS TO THE CLAIMS**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-15. (Cancelled)

16. (Previously Presented) A peptide consisting of the formula;

$X_1X_2X_3RX_4LX_5F$ (formula II) (SEQ ID No. 2)

wherein X_1 , X_3 , X_4 and X_5 are each a natural or unnatural amino acid and X_2 is serine or alanine.

17. (Withdrawn) A peptide according to claim 16, wherein X_5 is selected from isoleucine and glycine.

18. (Withdrawn) A peptide according to claim 16, wherein X_1 and X_4 are both basic amino acid residues and X_3 is a basic or polar residue.

19. (Withdrawn) A peptide according to claim 18, wherein X_1 is histidine and X_4 is arginine, and X_3 is lysine or cysteine.

20. (Currently Amended) A peptide consisting of the formula;



(SEQ ID No. 2)

wherein X_1 , X_3 , X_4 and X_5 are each a natural or unnatural amino acid and X_2 is serine or alanine, and wherein the peptide is

- (a) one amino acid residue is deleted~~modified by deletion of one or more amino acid residues;~~
- (b) one or more amino acid residues are substituted ~~modified by substitution of one or more natural amino acid residues~~ by the corresponding D-stereomer;
- (c) [[a]]the peptide is cyclic;
- (d) ~~modified by reversing the order of the final two residues at the C-terminal end~~ are reversed; or
- (e) any combination of (a)-(d).

21. (Withdrawn) A peptide consisting of the formula;



(SEQ ID No. 2)

wherein:

- (a) X_1 is deleted or is a natural or unnatural amino acid,
- (b) X_2 is serine or alanine or a straight or branched chain amino acid,
- (c) X_3 is a basic amino acid or straight chain aliphatic amino acid,
- (d) R is unchanged or conservatively substituted by a basic amino acid,
- (e) X_4 is an amino acid that is capable of providing at least one site for participating in hydrogen bonding,
- (f) L is unchanged or conservatively substituted,
- (g) X_5 is a natural or unnatural amino acid, or
- (h) F is unchanged or substituted by an aromatic amino acid.

22. (Withdrawn) A peptide consisting of the formula;



wherein

- (a) X_1 is deleted or is a natural or unnatural amino acid residue,
- (b) X_2 is a natural or unnatural amino acid residue having an aromatic or aliphatic side chain,
- (c) X_3 is a basic residue, or an uncharged natural or unnatural amino acid residue,
- (d) arginine is replaced by a basic residue or an uncharged natural or unnatural amino acid residue,
- (e) X_4 is a natural or unnatural amino acid residue, or an amino acid residue capable of forming a cyclic linkage,
- (f) leucine is replaced with a natural or unnatural amino acid residue having an aromatic or aliphatic side chain,
- (g) X_5 is a natural or unnatural amino acid residue having an aromatic or aliphatic side chain,
- (h) phenylalanine is replaced with a natural or unnatural amino acid,
- (i) X_5 and the terminal phenylalanine residue are reversed, or
- (j) the peptide is in cyclic form by the formation of a linkage between the side chain of X_4 and the C-terminus residue.

23. (Withdrawn) A peptide according to claim 16, wherein X_2 is alanine.

24. (Withdrawn) A peptide according to claim 16, wherein X_5 is isoleucine.

25. (Withdrawn) A peptide selected from the group consisting of:

H S K R R L I F (SEQ ID No. 34)

H A K R R L I F (SEQ ID No. 35)

H S K R R L F G (SEQ ID No. 36)

H A K R R L F G (SEQ ID No. 37)

K A C R R L F G (SEQ ID No. 38)

K A C R R L I F (SEQ ID No. 39)

	X1	X2	X3	R	X4	L	X5	F		
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 28)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 40)
	H-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 41)
H-	Pya-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 42)
H-	Thi-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 43)
H-	Hse-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 44)
H-	Phe-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 45)
H-	Dab-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 46)
H-	His-	Gly-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 47)
H-	His-	Abu-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 48)
H-	His-	Nva-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 49)
H-	His-	Bug-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 50)
H-	His-	Val-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 51)
H-	His-	Ile-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 52)
H-	His-	Phg-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 53)
H-	His-	Phe-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 54)
H-	His-	Ala-	Ala-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 56)
H-	His-	Ala-	Nle-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 57)
H-	His-	Ala-	Abu-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 58)
H-	His-	Ala-	Leu-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 59)
H-	His-	Ala-	Arg-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 60)
H-	His-	Ala-	Lys-	Ala-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 61)
H-	His-	Ala-	Lys-	Cit-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 62)
H-	His-	Ala-	Lys-	Hse-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 63)
H-	His-	Ala-	Lys-	His-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 64)
H-	His-	Ala-	Lys-	Nle-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 65)
H-	His-	Ala-	Lys-	Gln-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 66)
H-	His-	Ala-	Lys-	Lys-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 67)
H-	His-	Ala-	Lys-	Arg-	Ala-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 68)
H-	His-	Ala-	Lys-	Arg-	Asn-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 69)
H-	His-	Ala-	Lys-	Arg-	Pro-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 70)
H-	His-	Ala-	Lys-	Arg-	Ser-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 71)
H-	His-	Ala-	Lys-	Arg-	Aib-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 72)
H-	His-	Ala-	Lys-	Arg-	Sar-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 73)
H-	His-	Ala-	Lys-	Arg-	Cit-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 74)

H-	His-	Ala-	Lys-	Arg-	Arg-	Ala-	Ile-	Phe	-NH2	(SEQ ID No. 76)
H-	His-	Ala-	Lys-	Arg-	Arg-	Ileu-	Ile-	Phe	-NH2	(SEQ ID No. 77)
H-	His-	Ala-	Lys-	Arg-	Arg-	Ile-	Ile-	Phe	-NH2	(SEQ ID No. 78)
H-	His-	Ala-	Lys-	Arg-	Arg-	Val-	Ile-	Phe	-NH2	(SEQ ID No. 79)
H-	His-	Ala-	Lys-	Arg-	Arg-	Nle-	Ile-	Phe	-NH2	(SEQ ID No. 80)
H-	His-	Ala-	Lys-	Arg-	Arg-	Nva-	Ile-	Phe	-NH2	(SEQ ID No. 81)
H-	His-	Ala-	Lys-	Arg-	Arg-	Cha-	Ile-	Phe	-NH2	(SEQ ID No. 82)
H-	His-	Ala-	Lys-	Arg-	Arg-	Phe-	Ile-	Phe	-NH2	(SEQ ID No. 83)
H-	His-	Ala-	Lys-	Arg-	Arg-	1Nap-	Ile-	Phe	-NH2	(SEQ ID No. 84)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ala-	Phe	-NH2	(SEQ ID No. 85)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Leu-	Phe	-NH2	(SEQ ID No. 86)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Val-	Phe	-NH2	(SEQ ID No. 87)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Nle-	Phe	-NH2	(SEQ ID No. 88)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Nva-	Phe	-NH2	(SEQ ID No. 89)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Cha-	Phe	-NH2	(SEQ ID No. 90)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Phe-	Phe	-NH2	(SEQ ID No. 91)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	1Nap-	Phe	-NH2	(SEQ ID No. 92)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Leu	-NH2	(SEQ ID No. 95)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Cha	-NH2	(SEQ ID No. 96)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Hof	-NH2	(SEQ ID No. 97)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Tyr	-NH2	(SEQ ID No. 98)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 99)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	mFPhe	-NH2	(SEQ ID No. 100)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Trp	-NH2	(SEQ ID No. 101)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	1Nap	-NH2	(SEQ ID No. 102)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	2Nap	-NH2	(SEQ ID No. 103)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Lys	-NH2	(SEQ ID No. 104)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Tic	-NH2	(SEQ ID No. 105)
H-	His-	Ala-	Lys	Arg	Arg	Leu	Ile	L-Pse	OH	(SEQ ID No. 106)
H-	His-	Ala-	Lys	Arg	Arg	Leu	Ile	D-Pse	OH	(SEQ ID No. 107)
H-	His-	Ser	Lys	Arg	Arg	Leu	Ile	L-Pse	OH	(SEQ ID No. 108)
H-	His-	Ser	Lys	Arg	Arg	Leu	Ile	D-Pse	OH	(SEQ ID No. 109)
H-	His-	Ala	Lys	Arg	Arg	Leu	Ile	L-Psa	OH	(SEQ ID No. 110)
H-	His-	Ala	Lys	Arg	Arg	Leu	Ile	D-Psa	OH	(SEQ ID No. 111)
H-	His-	Ser	Lys	Arg	Arg	Leu	Ile	L-Psa	OH	(SEQ ID No. 112)
H-	His-	Ser	Lys	Arg	Arg	Leu	Ile	D-Psa	OH	(SEQ ID No. 113)
H-	His-	Ala	Lys	Arg	Arg	Leu	Ile	Dhp	OH	(SEQ ID No. 114)
H-	His-	Ser	Lys	Arg	Arg	Leu	Ile	Dhp	OH	(SEQ ID No. 115)
H-	His-	Ala	Lys	Arg	Arg	Leu	Ile	Pheol		(SEQ ID No. 116)
H-	His-	Ser	Lys	Arg	Arg	Leu	Ile	Pheol		(SEQ ID No. 117)
H-	Ala-	Ala-	Abu-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 118)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 119)
H-	Ala-	Ala-	Lys-	Arg-	Cit-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 120)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ala-	pFPhe	-NH2	(SEQ ID No. 121)
H-	Ala-	Ala-	Abu-	Arg-	Ser-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 122)
H-	Ala-	Ala-	Lys-	Gln-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 123)

H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 124)
H-	Gly-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 125)
H-	Ala-	Ala-	Lys-	hArg-	Arg-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 126)
H-	Ala-	Ala-	Lys-	Ser-	Arg-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 127)
H-	Ala-	Ala-	Lys-	Hse-	Arg-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 128)
H-	Ala-	Ala-	Lys-	Arg-	Lys-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 129)
H-	Ala-	Ala-	Lys-	Arg-	Orn-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 130)
H-	Ala-	Ala-	Lys-	Arg-	Gln-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 131)
H-	Ala-	Ala-	Lys-	Arg-	Hse-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 132)
H-	Ala-	Ala-	Lys-	Arg-	Thr-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 133)
H-	Ala-	Ala-	Lys-	Arg-	Nva-	Leu-	Ile-	pFPhe	-NH2 (SEQ ID No. 134)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Phg-	Ile-	pFPhe	-NH2 (SEQ ID No. 135)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Met-	Ile-	pFPhe	-NH2 (SEQ ID No. 136)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Ala-	Ile-	pFPhe	-NH2 (SEQ ID No. 137)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Hof-	Ile-	pFPhe	-NH2 (SEQ ID No. 138)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	hLeu-	Ile-	pFPhe	-NH2 (SEQ ID No. 139)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	alle-	Ile-	pFPhe	-NH2 (SEQ ID No. 140)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Gly-	pFPhe	-NH2 (SEQ ID No. 141)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	βAla	pFPhe	-NH2 (SEQ ID No. 142)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Phg-	pFPhe	-NH2 (SEQ ID No. 143)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Aib-	pFPhe	-NH2 (SEQ ID No. 144)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Sar-	pFPhe	-NH2 (SEQ ID No. 145)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Pro-	pFPhe	-NH2 (SEQ ID No. 146)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Bug-	pFPhe	-NH2 (SEQ ID No. 147)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ser-	pFPhe	-NH2 (SEQ ID No. 148)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Asp-	pFPhe	-NH2 (SEQ ID No. 149)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Asn-	pFPhe	-NH2 (SEQ ID No. 150)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	pFPhe-	Phe	-NH2 (SEQ ID No. 151)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	diClPhe	Phe	-NH2 (SEQ ID No. 152)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	pClPhe-	Phe	-NH2 (SEQ ID No. 153)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	mClPhe	Phe	-NH2 (SEQ ID No. 154)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	oClPhe-	Phe	-NH2 (SEQ ID No. 155)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	pIPhe-	Phe	-NH2 (SEQ ID No. 156)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	TyrMe-	Phe	-NH2 (SEQ ID No. 157)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Thi-	Phe	-NH2 (SEQ ID No. 158)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Pya-	Phe	-NH2 (SEQ ID No. 159)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	diClPhe	-NH2 (SEQ ID No. 160)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pClPhe	-NH2 (SEQ ID No. 161)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	mClPhe	-NH2 (SEQ ID No. 162)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	oClPhe	-NH2 (SEQ ID No. 163)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phg	-NH2 (SEQ ID No. 164)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	TyrMe	-NH2 (SEQ ID No. 165)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Thi	-NH2 (SEQ ID No. 166)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Pya	-NH2 (SEQ ID No. 167)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Inc	-NH2 (SEQ ID No. 168)

and the cyclic peptides:

5,8-cyclo-[H-His-Ala-Lys-Arg-Lys-Leu-Phe-Gly]	(SEQ ID No. 169)
5,8-cyclo-[H-His-Ala-Lys-Arg-Orn-Leu-Phe-Gly]	(SEQ ID No. 170)

26-35. (Cancelled)

36. (Withdrawn) An assay for the identification of compounds that interact with a cyclin or a cyclin when complexed with the physiologically relevant CDK, comprising;

(a) incubating a candidate compound and a peptide consisting of formula II

$X_1X_2X_3RX_4LX_5F$ (SEQ ID No. 2)

wherein X_1 , X_3 , X_4 and X_5 are each a natural or unnatural amino acid and X_2 is serine or alanine and a cyclin or cyclin/CDK complex;

(b) detecting binding of either the candidate compound or the peptide of formula II with cyclin.

37-40. (Cancelled)

41. (Withdrawn) An assay according to claim 36, wherein the cyclin is selected from cyclin A, cyclin E or cyclin D.

42. (Withdrawn) An assay according to claim 41 wherein the cyclin is cyclin A.

43. (Cancelled)

44. (Withdrawn) An assay according to claim 36, wherein at least one of the assay components is bound to a solid phase.

45. (Withdrawn) An assay according to claim 44, wherein the p21 derived peptide is labeled such as to emit a signal when bound to said cyclin.

46. (Withdrawn) An assay according to claim 44, wherein the cyclin is labeled such as to emit a signal when bound to the p21 derived peptide.

47. (Withdrawn) An assay according to claim 45, wherein one of the assay components is labeled with a fluorescence emitter and the signal is detected using fluorescence polarisation techniques.

48-54. (Cancelled)

55. (Withdrawn) A peptide according to claim 22, wherein X_1 is selected from the group consisting of histidine, alanine, 3-pyraldylalanine (Pya), 2-thienylalanine (Thi), homoserine (Hse), phenylalanine and diaminobutyric acid (Dab).

56. (Withdrawn) A peptide according to claim 22, wherein X_2 is selected from the group consisting of alanine, glycine, aminobutyric acid (Abu), norvaline (Nva), t-butylglycine (Bug), valine, phenylglycine (Phg) and phenylalanine.

57. (Withdrawn) A peptide according to claim 22, wherein X_3 is selected from the group consisting of lysine, arginine, norleucine (Nle), aminobutyric acid (Abu) and leucine.

58. (Withdrawn) A peptide according to claim 22, wherein arginine is replaced by lysine, citrulline (Cit), homoserine, histidine, norleucine (Nle) or glutamine.

59. (Withdrawn) A peptide according to claim 22, wherein X_4 is selected from the group consisting of arginine, asparagines, praline, serine, aminoisobutyric acid (Aib), sarcosine, lysine and ornithine.

60. (Withdrawn) A peptide according to claim 22, wherein leucine is replaced by norleucine, norvaline, cyclohexylalanine (Cha), phenylalanine or 1-naphthylalanine (1Nal).

61. (Withdrawn) A peptide according to claim 22, wherein X_5 is selected from the group consisting of isoleucine, norleucine, norvaline, cyclohexylalanine (Cha), phenylalanine and 1-naphthylalanine (1Nal).

62. (Withdrawn) A peptide according to claim 22, wherein phenylalanine is replaced by leucine, cyclohexylalanine (Cha), homophenylalanine (Hof), tyrosine, para-fluorophenylalanine (pFPhe), meta-fluorophenylalanine (mFPhe), tryptophan, i-naphthylalanine (1Nal), 2-naphthylalanine (2Nal), biphenylalanine (Bip) or (Tic).

63. (Withdrawn - Currently Amended) The peptide of claim 20, wherein one amino acid residue is deleted ~~the peptide is modified by deletion of one or more amino acid residues.~~

64. (Withdrawn - Currently Amended) The peptide of claim 20, wherein one or more natural amino acid residue is substituted ~~the peptide is modified by substitution of one or more natural amino acid residues by the corresponding D-stereomer.~~

65. (Withdrawn - Currently Amended) The peptide of claim 20, wherein the peptide is $[[a]]$ cyclic.

66. (Withdrawn - Currently Amended) The peptide of claim 20, wherein ~~the peptide is modified by reversing the order of the final two residues at the C-terminal end~~ are reversed.

67. (Withdrawn) The peptide of claim 21, wherein X_1 is deleted or is a natural or unnatural amino acid.

68. (Withdrawn) The peptide of claim 21, wherein X_2 is serine or alanine or a straight or branched chain amino acid.

69. (Withdrawn) The peptide of claim 21, wherein X_3 is a basic amino acid or straight chain aliphatic amino acid.

70. (Withdrawn) The peptide of claim 21, wherein R is unchanged or conservatively substituted by a basic amino acid.

71. **(Withdrawn)** The peptide of claim 21, wherein X_4 is an amino acid that is capable of providing at least one site for participating in hydrogen bonding.
72. **(Withdrawn)** The peptide of claim 21, wherein L is unchanged or conservatively substituted.
73. **(Withdrawn)** The peptide of claim 21, wherein X_5 is a natural or unnatural amino acid.
74. **(Withdrawn)** The peptide of claim 21, wherein F is unchanged or substituted by an aromatic amino acid.
75. **(Withdrawn)** The peptide of claim 22, wherein X_1 is deleted or is a natural or unnatural amino acid residue.
76. **(Withdrawn)** The peptide of claim 22, wherein X_2 is a natural or unnatural amino acid residue having an aromatic or aliphatic side chain.
77. **(Withdrawn)** The peptide of claim 22, wherein X_3 is a basic residue, or an uncharged natural or unnatural amino acid residue.
78. **(Withdrawn)** The peptide of claim 22, wherein arginine is replaced by a basic residue or an uncharged natural or unnatural amino acid residue.
79. **(Withdrawn)** The peptide of claim 22, wherein X_4 is a natural or unnatural amino acid residue, or an amino acid residue capable of forming a cyclic linkage.
80. **(Withdrawn)** The peptide of claim 22, wherein leucine is replaced with a natural or unnatural amino acid residue having an aromatic or aliphatic side chain.
81. **(Withdrawn)** The peptide of claim 22, wherein X_5 is a natural or unnatural amino acid residue having an aromatic or aliphatic side chain.

82. **(Withdrawn)** The peptide of claim 22, wherein phenylalanine is replaced with a natural or unnatural amino acid.

83. **(Withdrawn)** The peptide of claim 22, wherein X_5 and the terminal phenylalanine residue are reversed.

84. **(Withdrawn)** The peptide of claim 22, wherein the peptide is in cyclic form by the formation of a linkage between the side chain of X_4 and the C-terminus residue.